Designing an effective formulation for drugs is one of the key challenges faced by pharmaceutical companies owing to a number of factors such as poor solubility, gastrointestinal side effects, instability, and low bioavailability. Thus, pharmaceutical companies are increasingly focusing on research and development of novel formulations and delivery systems that can blow life into older systems while also achieving the same or higher level of efficiency, a high level of bioavailability, solubility, lower side effects, and an enhanced level of safety. One relatively novel and rapidly evolving means of enhancing the delivery of drugs is the employment of therapeutic nanoemulsions during the formulation as well as discovery of new therapeutic agents.

Nanoemulsions refer to the kinetically stable translucent dispersions of oil in water or water in oil stabilized with the help of an interfacial film of surfactants and cosurfactants. Owing to the small size of droplets, nanoemulsions are believed to be stable against factors such as coalescence, flocculation, and creaming or sedimentation. Nanoemulsions also possess several appealing pharmaceutical and biological properties such as biocompatibility, biodegradation, ease of production, and physical stability.

In a recent market research report, Transparency Market Research (TMR) estimates that the global market for nanoemulsions will expand at a promising pace, especially when it comes to applications in the field of medicine. TMR projects that the market will expand at an impressive CAGR of 9.2% from 2017 and 2025, rising from a valuation of US$6.78 bn in 2016 to an opportunity of US$14.91 bn by 2025.

What key factors will lead to growth opportunities in the global nanoemulsions market?

Other than the obvious benefits of nanoemulsions, several factors are working in the favor of the global nanoemulsions market and its applications in medical and other industries such as cosmetics and food and beverages. Factors such as technological progress in the biotechnology and pharmaceutical industries, the rising rate of prevalence of a number of chronic diseases, rising awareness regarding the possible methods and means of treating chronic conditions, and the increased focus on the development of targeted delivery systems. Supportive government policies that are encouraging the development of the healthcare sector in developing economies and the rapid rate of new product launches are also driving the market.

Moreover, the nano size of particles in nanoemulsions makes them ideal for oral drugs as these medicines can be administered easily in small dosages, thus assuring the more efficient absorption of drugs and mitigating the potential threat of dose-related toxicity. Nanoemulsions have also been found suitable for use in parenteral administration owing to their excellent solubility in bio-degradable surfactants.

From a geographical perspective, the market for nanoemulsions in North America is presently the key contributor of revenue to the global market. The North America market is also expected to exhibit growth at a highly promising rate in the next few years. Several factors, such as the presence of well-established biotech and pharma industries, focus of pharma companies on research and development activities with the aim of developing novel drug varieties to outperform peers, and the rising prevalence of chronic diseases, are working in favor of the North America nanoemulsions market.

While North America is expected to continue to account for a significant share in the global nanoemulsions market in the next few years as well, it will be the market in Asia Pacific that will run the show. Rising disposable incomes and the changing demographic of several countries in the region, along with the rising rate of prevalence of chronic diseases will continue to lead to vast growth opportunities for novel drug delivery systems in the region, driving, in turn, the market for nanoemulsions.

The
global market for baking ingredients is intensely competitive due to
the existence of several companies. These market players are
excessively investing in developing new products to maintain their
market presence which only contributes to intensifying the market
competition. Some of the key players in the global baking ingredients
market include names such as CSM Bakery Solutions, British Bakels,
Puratos, Archer Daniels Midland Company, and Cargill Incorporated
among others. Recently, CSM Bakery Solutions, an international leader
in bakery ingredients, services, and products, teamed up with 3D
Systems Corporation, the initiators of 3D solutions and printing in
order to develop, sell, and distribute 3D materials, products, and
printers for the food sector. This global agreements permits the two
industry giants to join their forces and bring creative and
innovative 3D printed kosher products in the market. CSM will aid the
development of the 3D Systems’ ChefJet Pro 3D printer that will be
used for high resolution and colorful culinary products for the
professional environment. CSM Bakery will own the exclusive rights
for this product.

The
global market for baking ingredients material is expected to grow at
a healthy CAGR of 4.9% over the course of the given forecast period
of 2016 to 2024. The overall valuation of the global baking
ingredients market stood at about US$11.7 bn in the year 2015 and is
estimated to reach the total valuation of about US$18.1 bn by the end
of the forecast period. The flavor and color additives segment is
expected to grow at a CAGR of 5.6% over the aforementioned forecast
period.

Changing
food habits of customers across the world is pointed out to be the
chief driving factor for the development of the global baking
ingredients market in the near future. People now a days are more
inclined towards using baking ingredients such as flavors, fats,
color additives, flour, sweeteners, baking powder, baking soda, and
yeast. This increasing preference for baking ingredients backed by
substantial increase in the consumption of bakery items across North
America and Europe as staple food has significantly boosted the
growth of the global baking ingredients market. Moreover, the growing
purchasing power and increase in the disposable income of the youth
across the globe is projected to amplify the need for baked food
products such as pizzas, biscuits, and cakes. An increasing
preference for ready to eat meals and convenient snacks such as bread
rolls, wraps, and pocket sandwiches over other time consuming food
items is also projected to drive the global baking ingredients market
in the coming years.

However,
there are some factors that may pose some problem in the development
of the market. There has been a rising awareness among people about
their health and are becoming more fitness conscious. These people
are increasingly moving away from baked food products and thus,
impeding the market growth. However, growing adoption of western
lifestyle is anticipated to play an important part in the growth of
the market for baking ingredients over the course of given forecast
period.

At the point when resources should be expelled from the endeavor, they travel through different aura forms. Ordinarily they are given over to an IT Asset Disposition merchant to be reused or devastated. Resources ought to be overseen legitimately subsequent to going disconnected to guarantee they don't get lost before achieving the seller. The seller of decision should then have secure methodology for following resources amid the whole time of their ownership. After appropriate disposal, the merchant gives an endorsement of demolition with the serial quantities of benefits they devastated and reused. The organization should then check the serial numbers on their testament of pulverization with the benefits they know they gave over to the merchant. Following resources that are disconnected, preceding transfer, ought to be drawn nearer with an indistinguishable proficiency and security from when those same resources are on the web.

The global market for data center IT asset disposition market is anticipated to witness a 6.8% CAGR from 2017 to 2025. The market worth US$7.74 bn in 2016 and is likely to touch US$13.87 bn by 2025. The players in the market are focusing on implementing extensive marketing as well remarketing strategies to attract customers from different sections and regions.

Which factor is likely to have the maximum impact on the growth of the market in the long run?

Administrative compliances in a few nations to save the environment, developing need of data, heightening information security worries from old resources, and expanding appropriation of new innovation and Byod are a portion of the key elements driving the request in the worldwide data center IT asset disposition market. Then again, absence of mindfulness, high administration cost, and constraint of complete IT asset disposition strategies are a couple of difficulties deterring the worldwide data center IT asset disposition market from achieving its actual potential. All things considered, the sellers of this market are relied upon to increase new open doors from esteem recuperate from old resources and additionally vital associations and acquisitions of promising new participants.

Which product is likely to be the key revenue generator?

On the basis of asset-type, the global market for data center IT asset disposition is classified into SSD, desktops, laptops, line cards, GBIC, CPU, memory modules, HDD, and server. Amongst these, the segments of server, memory module, and SSD serve as the leading segments in the market and are likely to stay the same in the years ahead owing to the growth in the applications of big data, rising pool of data centers, and the development of cloud computing.

Stringent government directions and managed interest for information insurance has kept North America as the most gainful region among all, constituting for 34% of the market in 2015. The North America data center IT asset disposition market is anticipated to be worth US$4.40 bn before the finish of the gauge time frame, which is 2025, increasing most extreme request from the created nation of the U.S. IT resources are every now and again being changed because of consistent innovation updates inside cloud server farms in the locale, making the requirement for secure attitude. Europe is another productive district for the merchants working in the data center IT asset disposition market, driven by developing reusing and reuse of disposed of IT resources. The European locale watches strict natural strategies, which in this manner helps the mindfulness levels in regards to e-squander.

Regulatory maintenance of products that are already on the market or are in clinical trials is a highly exhaustive, complex, and time- and resource-consuming task, taking up a large share of a life sciences company’s regulatory resources every year. These activities, providing hardly any competitive advantage to the company, end-up restricting the company from employing its best regulatory resources onto innovations and core competencies.

As the global healthcare industry becomes increasingly competitive in terms of budget cuts, globalizations, and restructuring, life sciences companies are faced with unprecedented threats to their survival. The large and expanding product portfolios of life science companies, covering numerous verticals, make regulatory compliance for companies even tough. Companies have started to realize the need to focus on core competencies in order to sustain in the tough scenario. This factor has improved the scope of growth for the regulatory affairs outsourcing market.

In one of its recent market research reports, Transparency Market Research estimates that the global market for regulatory affairs outsourcing will expand at a promising CAGR of 11.5% over the period between 2015 and 2023. At this pace, the market could rise to an opportunity of US$5.7 bn by 2023 from US$1.9 bn in 2014.

In this blog post, TMR analysts analyze some of the key trends in the market, predicting how they will impact the overall development of the market in the next few years.

What are the key factors that will drive the market in the next few years?

Life sciences companies are most likely to resort to outsourcing regulatory affairs owing to factors such as cost competitiveness, effective results in diverse markets with a vast set of regulatory compliances governing several aspects related to drugs and medical devices. Presently, nearly 70% of the globe’s leading biotech and pharmaceutical companies have started to outsource their regulatory affairs. While this represents a significant portion of the market, it still has scope of expansion as a number of new and regional companies are looking to expand their business in the international market.

Opportunities abound chiefly in emerging economies such as India and China, which have thriving pharmaceutical and biotech companies and are the preferred locations for business expansion for international companies owing to low manufacturing costs. Asia Pacific also offers vast growth opportunities for the global regulatory affair outsourcing market owing to the presence of a large number of service providers.

Which kinds of regulatory affairs are most commonly outsourced by life science companies?

A variety of regulatory affair services are commonly outsourced by life sciences companies, including regulatory submissions, regulatory writing and publishing, and clinical trial applications and product registrations. Of these, the regulatory writing and publishing segment is the most commonly outsourced regulatory affair by life sciences companies. The segment accounted for over 40% of the revenue generated by the global regulatory affairs outsourcing market in 2014. The segment is expected to continue raking in vast demand in the near future as well, chiefly owing to the complex, diverse, and the rapidly evolving regulatory landscape of international, national, regional, and domestic markets.

In the near future, however, the segment of clinical trial applications and product registrations is expected to take over as the most promising area of regulatory affairs outsourcing. The segment will expand at the most promising pace and will present vast growth opportunities for regulatory affairs service providers. Factors such as rapid rate of introduction of new drugs, patent expiries, and the increased prevalence of several bacterial, viral, and chronic diseases, which has prompted biotech companies to focus more on novel products, will contribute to the rise in demand for clinical trial applications and product registrations services.

The number of patients suffering from opioid induced constipation has reached an alarming rate. In the U.S. alone, close to 100 mn patients were diagnosed to suffer from OIC in 2013 as per a report by the American Academy of Pain Medicine. The number is expected to increase with an increase in the number of people consuming opioid drugs. The commercial availability of opioid drugs has led to a large number of patients using them for treating chronic pains. According to a report published by Transparency Market Research (TMR), the global market for opioid induced constipation treatment is expected to rise from US$731.2 mn in 2016 to reach US$4.81 bn by the end of 2023. The market is expected to exhibit a stupendous CAGR of 31.2% from 2015 to 2023.

Given below are answers to three vital questions pertaining to the global opioid induced constipation treatment market, answered by TMR experts.

Q. Which drug class is expected to emerge as most popular in the years to come?

In 2016, the chloride channel activators was the most popular drug class of opioid induced constipation treatments on account of the high sales of Amitiza. The demand for chloride channel activators will continue to rise, however, the mu-opioid receptor antagonists segment will lead in the coming years. The greater efficacy of mu-opioid receptor antagonists and the growing number of approval for this drug class is expected to be the reason for the growth of this segment. The growing number of prescriptions being filed for opioid induced constipation treatments as they have less side effects will also be a reason for the demand of this drug class.

Q. Which region will prove to be most lucrative in the opioid induced constipation treatment market?

North America is not only leading at present but is estimated to continue to lead in the years to come. The legal acceptance of opioids for pain treatment in the U.S. is expected to be a key reason behind the growth of the market in the region. The high number of patients suffering from opioid induced constipation in the region will be a key reason for the growth of the North American OIC treatment market. It is estimated that North America will generate US$4.05 bn in revenue by 2023. Other regions have very low awareness rates of available opioid induced constipation treatments. This is also another reason for the growth of North American opioid induced constipation treatment market.

Q. What is the biggest challenge hampering the growth of the global opioid induced constipation treatment market?

One of the biggest challenges for the global opioid induced constipation treatment market is the widespread use of laxatives for treatment. The high price of opioid induced constipation treatment drugs is expected to be a key challenge for the growth of this market. The price of standard laxatives is much cheaper and this disparity in pricing between standard laxatives and OIC treatment drugs will be a major challenge for the market’s growth. In addition to this, many of the opioid induced constipation treatment drugs cause side effects such as nausea and increase the risk of heart problems and strokes, posing another challenge.

Nonalcoholic Steatohepatitis (NASH) refers to a liver syndrome found in non-alcoholic patients that damages the liver, rendering it like the liver in alcoholic hepatitis. NASH results from the accumulation of fat in the liver, along with inflammation. Symptoms are not shown in early stages and the condition could lead to cirrhosis, causing permanent liver damage. People suffering from conditions such as glucose intolerance, obesity, and dyslipidemia run a high risk of causing nonalcoholic steatohepatitis (NASH). As most NASH patients are asymptomatic, biopsy is most often required to confirm the diagnosis.

In a recent report, Transparency Market Research (TMR) estimates that the global market for nonalcoholic steatohepatitis will tread along a healthy growth path in the next few years. A number of factors are working in the favor of the market and the rising pool of patients is compelling biotech and pharmaceutical companies to invest in research and development of effective diagnosis and treatment methods for the condition. The market is witnessing an encouraging rise in the number of drugs available to treat the conditions and diagnosis is becoming more accurate.

In its report, TMR states that the global NASH market will exhibit a 10.7% CAGR from 2015 and 2025, rising to an opportunity of US$20.27 bn by 2025.

In this blog post, TMR analysts highlight some of the key trends and opportunities in the global NASH market:

Q. What factors will contribute majorly to the growth of the market in the near future?

A. The NASH market is presently at a nascent stage of development as there are not many U.S. FDA-approved drugs for the disease currently in the global marketplace. However, the market is expected to grow steadily over the coming years as a number of potential drug candidates for NASH are currently in the pipeline at Phase II and III.

The NASH market will also benefit from the fact that healthcare authorities are becoming increasingly concerned about mitigating the larger impact of NASH on the population as well as the socio-economic impact of the disease. This concern stems from the high risk of NASH patients’ condition progressing into cirrhosis. As per information published by the American Liver Foundation, these patients also stand a high risk of developing HCC or hepatocellular cancer. With this becoming a concern, more efforts are expected to be deployed for treating the disease in the near future.

Q. How are biotech and pharma companies responding to opportunities in the global NASH market?

A. The diagnosis and treatment of NASH presents a sizeable opportunity for companies in the pharmaceutical and biotech sector. Factors such as the vast rise in the number of non-alcoholic fatty liver disease (NAFLD) cases (which could lead to NASH), increasing incidence of obesity, and changes in lifestyles of the global population are all eventually projected to act as growth drivers for the global NASH market. This gives companies an opportunity to explore new avenues for growth in the global nonalcoholic steatohepatitis market.

In the long run, the growth of the NASH market will also be driven due to the fact that NASH is associated with morbid conditions such as insulin resistance and obesity. This indicates a massive unmet demand for drugs and therapeutic treatments for NASH, creating new revenue-generation areas for companies in the market. There is immense scope for novel therapies and formulations to be launched in the global nonalcoholic steatohepatitis market. Thus, innovation will remain the cornerstone of growth for companies vying for a higher share of revenue in the global NASH market.

The medical tourism market in Malaysia is driven by the growing influx of medical tourists from the MENA region and its neighboring countries, which has resulted in the exponential rise in medical tourism in the country. The cost of medical services is low in Malaysia as compared to the developed nations in Europe and North America. This will also act as a chief factor causing foreign medical tourists to come to Malaysia, driving the medical tourism market in the nation. The government initiatives to boost this sector are also aiding the growth of the market. Due to all these factors, the medical tourism market in Malaysia is expected to rise from US$424.96 mn in 2016 to US$3.5 bn by 2024, expanding at a whopping 30.05% CAGR between 2017 and 2024, as per a report published by Transparency Market Research (TMR).

In the blog post below, experts from TMR answer three pressing questions regarding the medical tourism industry in Malaysia:

Q. What are the factors boosting the growth of the Malaysian medical tourism market?

There are a few macroeconomic factors that have a role to play in fueling the growth of the Malaysian medical tourism market such as the excellent transport facilities, recuperation facilities, tax incentives offered by the government, especially on the revenue generated from foreign patients. In 2010, government offered tax exemption of full 100% on the revenues earned from foreign patients. Low language barrier is another reason behind the growth of this industry in the country. With the motto of wooing patients from the Middle East, Malaysia offers halal medical services, under which a whole range of Muslim friendly services are offered. This is attracting patients from nations with Islam dominance. Additionally, the sophisticated healthcare infrastructure provided in Malaysia will be a key growth driver for the medical tourism industry. All these factors are estimated to continue to auger the growth of the medical tourism market, which is considered one of the 12 national key economic areas (NKEA) in Malaysia.

Among procedure types such as medical check-ups, neurology, regenerative therapy, cosmetic surgery, ophthalmology, dental treatment, orthopedic treatment, fertility treatments, oncology, cardiothoracic surgery, and cardio, the dental treatment followed by the cosmetic surgery segment is leading in Malaysia. As of 2016, it has been estimated that over 36.6% medical tourists visiting Malaysia opt for dental treatment. Low cost as compared to treatment offered in the U.S. and favorable government regulations are behind the growth of the segment. In the years to come the health screening and orthopedic treatment segments will also account for significant shares in the market.

Q. Which factors will restrain the growth of this market?

There has been a slight drop in the number of medical travelers in Malaysia. The medical inflation recorded in 2015 is another factor which hampered the growth of this market. The revenue generated per patient is low and the healthcare cost is escalating. All these factors are posing a challenge for the healthcare system in Malaysia.